Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
Kun Wang, Albert Cheung Hoi Yu, Kewei Liu, et al.
Advanced Science (2023) Vol. 10, Iss. 13
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions
Xingchen Li, Wenzhi Tian, Zhongxing Jiang, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 2
Open Access | Times Cited: 18
Cell Membrane as A Promising Therapeutic Target: From Materials Design to Biomedical Applications
Xiaofeng Wu, Jingjing Hu, Juyoung Yoon
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 18
Closed Access | Times Cited: 17
Sonocatalytic oncolysis microbiota curb intrinsic microbiota lactate metabolism and blockade CD24-Siglec10 immune escape to revitalize immunological surveillance
Xiulin Dong, Hui Liu, Chao Fang, et al.
Biomaterials (2024) Vol. 311, pp. 122662-122662
Closed Access | Times Cited: 11
Chemically engineered antibodies for autophagy-based receptor degradation
Binghua Cheng, Meiqing Li, Jiwei Zheng, et al.
Nature Chemical Biology (2025)
Closed Access | Times Cited: 1
Progress in PRRSV Infection and Adaptive Immune Response Mechanisms
Huanchang Cai, Hewei Zhang, H. N. Cheng, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1442-1442
Open Access | Times Cited: 19
Targeted degradation of extracellular secreted and membrane proteins
Xuankun Chen, Yaxian Zhou, Yuan Zhao, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 762-775
Open Access | Times Cited: 16
Research progress in nano-drug delivery systems based on the characteristics of the liver cancer microenvironment
Shijia Lu, Chenxiao Zhang, Jinglong Wang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 170, pp. 116059-116059
Open Access | Times Cited: 15
Cell Membrane as A Promising Therapeutic Target: From Materials Design to Biomedical Applications
Xiaofeng Wu, Jingjing Hu, Juyoung Yoon
Angewandte Chemie (2024) Vol. 136, Iss. 18
Closed Access | Times Cited: 5
Biochemical and biophysical mechanisms macrophages use to tune phagocytic appetite
Annalise Bond, Meghan A. Morrissey
Journal of Cell Science (2025) Vol. 138, Iss. 1
Closed Access
Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics
Lisha Ou, Mekedlawit Setegne, Jeandele Elliot, et al.
Chemical Reviews (2025)
Closed Access
A Plug‐and‐Play Ferritac Platform Degrading Membrane Proteins via Receptor Crosslinking
Qunye He, Lei Wang, Lulu Huang, et al.
Advanced Functional Materials (2025)
Closed Access
Bioengineered ferritin-based LYTAC platform for tumor-targeted therapy
Kelong Fan, Shuai Zhang, Yiliang Jin, et al.
Research Square (Research Square) (2025)
Closed Access
Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma
Xulei Huo, Sihan Ma, Can Wang, et al.
Clinical and Translational Medicine (2023) Vol. 13, Iss. 10
Open Access | Times Cited: 9
Sonodynamic Nano-LYTACs Reverse Tumor Immunosuppressive Microenvironment for Cancer Immunotherapy
Mengke Xu, Yuxuan Hu, Jiayan Wu, et al.
Journal of the American Chemical Society (2024)
Closed Access | Times Cited: 3
Targeted Protein Degradation Mediated by Genetically Engineered Lysosome-Targeting Exosomes
Tao Wang, Liang Sun, Tianyu Ren, et al.
Nano Letters (2023) Vol. 23, Iss. 20, pp. 9571-9578
Closed Access | Times Cited: 7
Targeting the CD24-Siglec10 Axis: A Potential Strategy for Cancer Immunotherapy
Junyue Fang, Lin Li, Yuan Cao, et al.
BIO Integration (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 2
New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer
Zhi Li, Xi Yu, Zeting Yuan, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189152-189152
Closed Access | Times Cited: 2
Unravelling CD24‐Siglec‐10 pathway: Cancer immunotherapy from basic science to clinical studies
Rudradeep Hazra, Soumyadeep Chattopadhyay, Arijit Mallick, et al.
Immunology (2024) Vol. 173, Iss. 3, pp. 442-469
Closed Access | Times Cited: 2
Predicting response to anti-EGFR antibody, cetuximab, therapy by monitoring receptor internalization and degradation
Yejin Sung, Seung Taek Hong, Mihue Jang, et al.
Biomaterials (2023) Vol. 303, pp. 122382-122382
Open Access | Times Cited: 6
Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors
Qiangfeng Wang, Yumeng Zhu, Junping Pei
Future Medicinal Chemistry (2024) Vol. 16, Iss. 18, pp. 1923-1944
Closed Access | Times Cited: 1
Hepatocyte targeting via the asialoglycoprotein receptor
Fabricio Ramírez-Cortés, Petra Ménová
RSC Medicinal Chemistry (2024)
Open Access | Times Cited: 1
Impact of the Siglec-Sialoglycan Axis on the Cancer Immune Response
Mohammed Saqif Ahmad, Sara Seriah, Shoib Sarwar Siddiqui
Interdisciplinary cancer research (2024)
Closed Access
The potential of biomimetic nanoparticles for macrophage repolarisation and phagocytosis in tumour immunotherapy
Zhihong Sun, Rui Zhou, Jie Liu, et al.
Chemical Engineering Journal (2024) Vol. 497, pp. 154506-154506
Closed Access
Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics
Wutong Zhao, Yongbin Jiang, Xiufen Li, et al.
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology (2024) Vol. 16, Iss. 6
Closed Access
Page 1 - Next Page

Scroll to top